A phase 2 study of tandutinib in patients with newly diagnosed acute myelogenous leukemia who are considered ineligible for or who decline treatment with standard induction therapy

Trial Profile

A phase 2 study of tandutinib in patients with newly diagnosed acute myelogenous leukemia who are considered ineligible for or who decline treatment with standard induction therapy

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2013

At a glance

  • Drugs Tandutinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2008 Status changed from in progress to withdrawn prior to recruitment.
    • 08 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top